Senate LDA lobbying filing
Eli Lilly and Company
Filed as: ELI LILLY AND COMPANY — THE SIMMONS & RUSSELL GROUP, LLC. Search lda.senate.gov for those strings; the names above are this site’s casing of them, nothing else.
Reported income
$60.0K
Reported expenses
not reported
Connections in the record
Tracked program mentions1
Quoted activity text is clipped to a short extract; each filing’s full description is under Lobbying activities below.
Issues related to the pharmaceutical industry including healthcare policy, drug pricing, drug value, insulin, and the…
Lobbying activities2
PharmacyPHA
Issues related to the pharmaceutical industry including healthcare policy, drug pricing, drug value, insulin, and the 340B Program. Monitoring implementation of the Inflation Reduction Act of 2022, H.R.5376, P.L.117-169. Monitoring implementation of the Infrastructure Investment and Jobs Act, H.R.3684, P.L.117-58. Issues related to obesity reduction. Issues related to Alzheimers coverage and access. Issues related to PBM reform.
Taxation/Internal Revenue CodeTAX
Issues related to tax legislation; Tax Relief for American Families and Workers Act of 2024, H.R.7024.
Lobbyists2
- KYLE SIMMONS
- ROBERT RUSSELL
Source: U.S. Senate Lobbying Disclosure Act database. Underlined dollar figures cite the filing record on lda.senate.gov and open to that citation. Amounts shown as “not reported” are absent from the filing itself.